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Background & Aims: The prevalence of nonalcoholic steatohepatitis (NASH) 3 
associated hepatocellular carcinoma (HCC) is increasing. However, strategies for 4 
detection of early-stage HCC in patients with NASH have limitations. We assessed 5 
the ability of the GALAD score, which determines risk of HCC based on patient sex; 6 
age; and serum levels of alpha-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-7 
gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. 8 
 9 
Methods: We performed a case-control study of 126 patients with HCC (20% within 10 
Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in 11 
Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD 12 
score to identify patients with HCC using receiver operating characteristic curves and 13 
corresponding area under the curve (AUC) analyses. We also analyzed data from 14 
389 patients with NASH under surveillance for HCC in Japan, followed for a median 15 
167 months. During the 5-year screening period, 26 patients developed HCC. To 16 
compensate for irregular intervals of data points, we performed locally weighted 17 
scatterplot smoothing, linear regression, and a non-linear curve fit to assess 18 
development of GALAD before HCC development. 19 
 20 
Results: The GALAD score identified patients with any stage HCC with an AUC of 21 
0.96 — significantly greater than values for serum levels of AFP (AUC, 0.88), AFP-L3 22 
(AUC, 0.86) or DCP (AUC, 0.87). AUC values for the GALAD score were consistent 23 
in patients with cirrhosis (AUC, 0.93) and without cirrhosis (AUC, 0.98). For detection 24 
of HCC within Milan Criteria, the GALAD score achieved an AUC of 0.91, with a 25 
sensitivity of 68% and specificity of 95% at a cut-off of -0.63. In a pilot Japanese 26 
cohort study, the mean GALAD score was higher in patients with NASH who 27 
developed HCC than in those who did not develop HCC as early as 1.5 years before 28 
HCC diagnosis. GALAD scores were above -0.63 approximately 200 days before the 29 
diagnosis of HCC.  30 
 31 
Conclusions: In a case–control study performed in Germany and a pilot cohort study 32 
in  Japan, we found the GALAD score may detect HCC with high levels of accuracy 33 
in patients with NASH, with and without cirrhosis. The GALAD score can detect 34 
patients with early-stage HCC, and might facilitate surveillance of patients with 35 
NASH, who are often obese, which limits the sensitivity of detection of liver cancer by 36 
ultrasound. 37 
 38 
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Need to Know: 2 
BACKGROUND AND CONTEXT: The performance of ultrasound screening for 3 
hepatocellular carcinoma (HCC) is limited, especially in patients with nonalcoholic 4 
steatohepatitis (NASH).  5 
 6 
NEW FINDINGS: In a retrospective analysis of patients with NASH in Germany, the 7 
GALAD score (based on patient features and laboratory test results) detected HCC 8 
(even early-stage tumors) with greater than 90% sensitivity and specificity—higher 9 
values than for any biomarker alone. In a prospective study, the GALAD score 10 
identified patients who developed HCC as early as 1.5 y before their diagnosis.  11 
 12 
LIMITATIONS: The number of patients with early-stage HCCs was small and the 13 
frequency of liver cirrhosis in our HCC population might not be typical.  14 
 15 
IMPACT: The GALAD score might be used in surveillance for HCC in patients with 16 
NASH. 17 
 18 
Lay Summary: Analysis of several factors, including patient sex, age, and blood 19 
levels of several proteins, can identify patients with NASH who are at high risk for 20 
HCC. 21 
  22 
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INTRODUCTION  1 
In industrialized countries, non-alcoholic steatohepatitis (NASH) is seen as a major 2 
risk factor for increasing incidence of hepatocellular carcinoma (HCC)1, 2. The current 3 
American Association for the Study of Liver Diseases (AASLD) HCC guidelines 4 
recommend surveillance by ultrasound (USS) with or without alpha-fetoprotein 5 
(AFP)3, given the inherent limitations of USS-based surveillance4-8. A recent meta-6 
analysis reported that using alpha fetoprotein (AFP) in combination significantly 7 
improves USS sensitivity to detect HCC at an early stage in patients with cirrhosis9.  8 
To address the insufficient performance of USS in HCC detection the GALAD score 9 
(gender, age, AFP-L3, AFP, DCP) was developed10. GALAD exhibited promising 10 
results for detection of early HCC in an initial prospective study10. A subsequent 11 
multicentre case-control study demonstrated that the GALAD model was superior to 12 
USS in early HCC detection, independent of etiology11. Although the latest AASLD 13 
guidelines note the potential of the GALAD score for HCC surveillance, it remarks on 14 
the need for phase III validation prior to adoption in routine clinical practice3. 15 
The limitations of USS alone for early detection of HCC are particularly evident in 16 
patients with NASH6. Serum–based biomarkers might be more effective, with or 17 
without USS, for HCC surveillance in NASH patients, although data in this patient 18 
population are currently lacking. The current study assessed the performance of the 19 
GALAD score for early HCC detection in patients with NASH-related liver disease. 20 
 21 




The study was approved by the institutional review board / ethics committee of each 1 
German center and the Japanese center and carried out in accordance with the 1964 2 
Helsinki Declaration.  3 
Retrospective case-control population 4 
The performance of the GALAD model was assessed in a case-control dataset from 5 
8 German centers including 357 patients with NASH. NASH was defined according to 6 
histological features, when available, or by presence of metabolic syndrome and 7 
absence of any history of significant alcohol intake, viral hepatitis, or other possible 8 
causes of liver disease12. Significant alcohol intake was defined as consumption of 9 
more than two drinks daily or more than six drinks daily on weekends for at least 5 10 
years13. The presence of HBV was excluded by qualitative sero-negativity for HbsAg 11 
and HCV exclusion was made by negative anti-HCV-IgG or HCV RNA. Cirrhosis was 12 
diagnosed either by histology or by overt clinical findings as portal hypertension in 13 
known chronic liver diseases. Details on this cohort are given in Supplementary 14 
Material. 15 
Prospective cohort population 16 
We conducted a pilot phase III evalution of GALAD using data from a prospective 17 
cohort recruited at a single Japanese centre. NAFLD was diagnosed based on the 18 
latest AASLD guidelines14: 1) fatty change of the liver observable by imaging; 2) no 19 
marked alcohol drinking habit present (ethanol intake of <210g per week for men and 20 
<140g per week for women); 3) no other causes for fatty change of the liver present; 21 
and 4) no other chronic liver disease (HCV, HBV, primary biliary cholangitis, or 22 
autoimmune hepatitis). Details on this cohort are given in Supplementary Material. 23 
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Clinical assessment 1 
In both datasets, cirrhosis was diagnosed by histology or overt clinical findings 2 
including portal hypertension in the setting of known chronic liver disease. HCC was 3 
diagnosed according to the European Association for the Study of the Liver (EASL) 4 
guidelines via histology or by two different imaging modalities (dynamic contrast CT 5 
or MRI of the liver)15, 16. The Barcelona Clinic Liver Cancer (BCLC) staging system 6 
was used for HCC stage17. The GALAD score was calculated as described 7 
previously18.  8 
Statistical methods 9 
Statistical analyses were performed with R (https://www.r-project.org) or Prism 10 
(GraphPad, La Jolla, CA, USA). Patient characteristics were compared between 11 
patients with and without HCC using Wilcoxon signed rank tests (continuous 12 
variables) or -tests (dichotomous variables). The GALAD model and single 13 
biomarker models were compared using receiver operating characteristic (ROC) 14 
curves and corresponding area under the curves (AUC) calculated using the R 15 
package ROCR19. AUC were compared according to DeLong et al.20 with pROC21. 16 
The Youden's Index was calculated to identify the ideal cut-off for specific 17 
comparisons22. 18 
Longitudinal changes of GALAD prior HCC development were visualized via 19 
LOWESS (Locally Weighted Scatterplot Smoothing) plot. Since biomarker levels 20 
were assessed at irregular intervals before HCC diagnosis for each patient, linear 21 
regression models for each patient (square and cubic terms) were fitted. GALAD was 22 
used as a dependent variable and time to diagnosis as the explanatory variable. For 23 
each patient, model-predicted values at various time points were generated. Median 24 
8 
 
GALAD value of all patients at each time point was then calculated and 95% 1 
confidence intervals were produced by the bootstrap method. A non-linear fit model 2 
(with three parameters) was calculated over all available GALAD values prior HCC 3 
development with Prism. 4 
 5 
RESULTS 6 
German multicenter case-control study 7 
Patient Characteristics 8 
Three hundred fifty-seven patients with NASH were enrolled in the German 9 
multicenter case-control study, including 126 with and 231 without HCC 10 
(Supplementary Figure 1A). All demographic and clinical details on this cohort are 11 
given in Table 1. The patients without HCC had a median age of 52 years and a 12 
mean BMI of 29kg/m². NASH patients without HCC were male in 51.9% of cases; 13 
38.5 % presented with diabetes and 20.9 % with cirrhosis. NASH-HCC patients were 14 
significantly older with median age of 70.5 but had similar BMI of 29kg/m². The 15 
proportions of male sex (67.2%), diabetes (71.4%), and cirrhosis (76.2%) were 16 
significantly higher in NASH-HCC patients. 17 
GALAD performance for HCC detection at any stage 18 
Median levels of AFP, AFP-L3, DCP and the GALAD score were significantly higher 19 
in the NASH-HCC patients compared to NASH controls (Table 1). Common cut-offs 20 
of individual markers reached only moderate sensitivity for detection of HCC at any 21 
stage (AFP 56.8% cut-off: 10ng/ml, AFP-L3 56.8% cut-off: 10%, DCP 81.6% cut-off: 22 
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0.76ng/ml) at high respective specificities (98.7%; 96.5%; 87.88%). Overall 1 
diagnostic performance, as assessed by AUC, was significantly higher (p<0.0005 for 2 
all) for GALAD than each individual biomarker (Figure 1A). At the established cut-off 3 
of -0.63, he GALAD score achieved superior sensitivity of 84.8% at a specificity of 4 
95.2%23,24. For the current study a optimal cut-off of -1.334 (sensitivity: 91.2%, 5 
specificity: 90.9%) was identified by the highest Youden's Index (Supplementary 6 
Table 1).   7 
GALAD performance for HCC detection at an early stage 8 
Performance of GALAD and each biomarker in isolation were analyzed for early HCC 9 
detection, defined as BCLC stage A HCC (n=28). GALAD reached an AUC of 0.92 10 
for early HCC detection, which was superior to AFP (p=0.0021), AFP-L3 (p<0.0001), 11 
and DCP (p>0.5) (Figure 1B). The cut-off -0.63 achieved 72.4% sensitivity and 12 
95.2% specifiticity, whereas the newly calculated cut-off -1.334 achieved 86.2% 13 
sensitivity and 90.9% specificity. 14 
Results were similar when early HCC was defined using Milan criteria (n=25; 20% of 15 
all NASH-HCC), with GALAD achieving an AUC of 0.90 (Figure 1C). Sensitivity of 16 
68.0% and specificity of 95.2% were achieved at the common cut-off -0.63. The cut-17 
off -1.334 reached 84.0% sensitivity and 90.9% specificity.  18 
Performance of GALAD by cirrhosis status 19 
In the subgroup analysis of patients with cirrhosis (n=95 HCC and 49 controls), 20 
GALAD achieved an AUC of 0.93 for HCC detection at any stage, which was 21 
significantly higher than AFP (AUC 0.79; p=0.0003) , AFP-L3 (AUC 0.75; p<0.0001), 22 
and DCP (0.83; p=0.0033) (Figure 2A). For early, cirrhotic HCC detection (n=22 23 
10 
 
HCC), GALAD achieved an AUC of 0.85, with 68.2% sensitivity and 91.8% specificity 1 
at -0.63 cut-off. Among those with non-cirrhotic NASH (n = 30 HCC and 182 2 
controls), GALAD reached an AUC of 0.98 for HCC detection at any stage (Figure 3 
2B), with 93.3% sensitivity and 96.1% specificity at the cut-off -0.63. For early, non-4 
cirrhotic HCC detection (n=7 HCC), GALAD achieved an AUC of 0.94, with 85.7% 5 
sensitivity and 96.2% specificity at -0.63 cut-off.  6 
Japanese prospective cohort study 7 
Patient Characteristics 8 
392 patients with NAFLD were prospectively followed under surveillance for HCC. 9 
Among these 28 patients developed HCC after a median of 10.3  [range: 3.1-21.3] 10 
years from start of surveillance. GALAD values prior to HCC diagnosis were available 11 
for 26 patients, with median time to HCC from the earliest available GALAD of 31 12 
[range: 0-172] months. The 363 patients who did not develop HCC during 13 
surveillance had a median age of 68 and mean BMI of 25kg/m². Of these patients 14 
49.6% were male, 38.6% had diabetes, and 19.6% had cirrhosis. The 26 patients 15 
developing HCC under surveillance were 61.5 y old (median) and had a mean BMI of 16 
26.95kg/m². Patients with HCC development had a proportion of 80.8% males, 80.8% 17 
diabetic patients, and 34.6% with cirrhosis. For 17 patients more than one GALAD 18 
value was available prior HCC diagnosis with a median follow up of 9.8 [range: 3.2-19 
19.2] years until HCC developed.  20 
Pilot Phase III Evaluation of GALAD  21 
To estimate the time frame before HCC diagnosis, in which the GALAD could 22 
indicate HCC, available GALAD values of 28 patients who developed HCC were 23 
11 
 
plotted by date prior HCC diagnosis (Figure 3C). A non-linear fit through these data 1 
points suggested a cut-off -0.63 would have been exceeded 200 days prior HCC 2 
diagnosis (Figure 3D).  3 
Among 17 patients who had more than one set of biomarkers prior to HCC diagnosis 4 
(Supplementary Table 2; Supplementary Figure 1B) and 363 NASH controls 5 
(without HCC development during surveillance), changes in the GALAD score before 6 
HCC development are illustrated by LOWESS plot (Figure 3A) and aggregate curves 7 
generated by linear regression (Figure 3B). While incremental increase of GALAD 8 
over time also occurred in NAFLD controls, patients who developed HCC had 9 
significantly higher GALAD scores several years prior to HCC diagnosis and a strong 10 
increase within a shorter time frame prior to diagnosis.  11 
DISCUSSION 12 
At present, NAFLD affects 25% of the world population25. NAFLD patients exhibit a 13 
high rate of disease progression to NASH-cirrhosis and 5-10% of HCC cases are 14 
attributed to NASH26-28. No effective screening strategy for NASH-derived HCC 15 
exists29 with insufficient sensitivity of current USS and AFP based approaches to 16 
detect early HCC15, 17, 5. Surveillance of NASH patients for HCC is inadequate30, 31 in 17 
particular as hepatocarcinogenesis may occur even in the absence of cirrhosis2. In 18 
our international multicenter study the GALAD score was successfully tested for 19 
detection of early and non-cirrhotic HCC to address current limitations in early HCC 20 
detection in NASH.  21 
The GALAD model includes AFP, AFP-L3 and DCP, which combined are superior in 22 
HCC detection in Asian patients32, 33, and incorporates gender and age, since older 23 
age and male sex represent independent HCC risk factors34. The GALAD model 24 
12 
 
exhibited excellent performance in HCC detection in multiple validation studies, 1 
including very large cohorts and early stage HCC (BCLC 0/A) of various etiologies24, 2 
35
. In addition the GALAD model separated HCC from pancreatic 3 
adenocarcinoma/cholangiocarcinoma (AUROC: 0.95)24, suggesting that GALAD is 4 
specific for HCC. In a recent, large American cohort study by Yang et al., including 5 
patients from the Early Detection Research Network Phase 2 HCC Study, the 6 
performance of GALAD over all etiologies was significantly superior to USS for HCC 7 
detection11. However, Yang et al. found only an AUC of 0.89 for NASH-specific HCC 8 
detection by GALAD, which was not significantly better than USS11. In the present 9 
multicenter study of NASH-HCC patients we demonstrate an excellent performance 10 
of the GALAD for detection of NASH HCC (AUC 0.96). The lower performance in the 11 
US-American cohort might be due to smaller group sizes (30 NASH-HCC, 49 non-12 
HCC NASH) in this etiology. Interestingly Yang et al.11 identified the ideal GALAD 13 
cut-off to detect NASH-HCC at -0.86, which is between the established cut-off and 14 
the one identified by us.   15 
GALAD can detect HCC independent of etiology, though insufficient data is available 16 
on a possible application for screening or detection of early stage HCC, in particular 17 
in NASH. Only 22.3% of the presented cohort comprised early stage HCC, similar to 18 
a previous study36, supporting the demand for an effective screening approach, to 19 
detect HCC at earlier stages. Despite the relatively low number of BCLC 0/A patients 20 
the GALAD score achieved a significantly better AUC (0.92) than individual 21 
biomarkers. We could also demonstrate that the performance of GALAD was 22 
independent of cirrhosis, as similar AUCs were achieved for patients without cirrhosis 23 
(AUC 0.98) or with cirrhosis only (AUC 0.93). When limiting the analysis further to 24 
HCC patients without cirrhosis and at BCLC stage 0/A (n=7) the GALAD score could 25 
13 
 
still separate NASH patients without cirrhosis with high sensitivity and specificity. 1 
Furthermore, GALAD could separate NASH HCC within Milan criteria from controls 2 
with good sensitivity and specificity. These data on NASH-HCC patients demonstrate 3 
that GALAD can detect HCC independent of cirrhosis or stage of HCC. Indeed, even 4 
early non-cirrhotic NASH-HCC seems clearly separable from NASH controls, as even 5 
small groups resulted in robust performance. The previously established, etiology 6 
spanning cut-off -0.63 reached good sensitivities and specifities in all analyses, while 7 
in our cohort a cut-off of -1.334 reached very high sensitivities and the highest sum of 8 
sensitivity and specificity, especially for early stage NASH HCC (Supplementary 9 
Table 1). Thus, we propose to apply the -1.334 cut-off in prospective multicentre 10 
studies for further validation. 11 
In addition to the retrospective data, GALAD was also tested in a prospectively 12 
recruited cohort of NAFLD patients under HCC surveillance. The GALAD was 13 
significantly higher in patients developing HCC during the observation period than in 14 
those without HCC formation. Different models were calculated for the surveillance 15 
data, demonstrating a sharp rise of the GALAD within few months prior HCC  16 
diagnosis. Depending on chosen cut-off detection of HCC could have been possible 17 
200 or even 560 days prior HCC diagnosis. While this specific result has to be 18 
confirmed in further prospective studies, it is a promising observation for potential use 19 
of GALAD as screening tool in NASH patients. 20 
Limitations of this study are the relatively low number of early stage BCLC 0/A cases, 21 
which would be the screening target group. However, analysis in this subgroup still 22 
yielded robust results and it should be noted that the base population is currently not 23 
screened in most centres. USS results were not available from participating German 24 
centres on the majority of patients. Frequency of liver cirrhosis in this HCC population 25 
14 
 
might not be typical, though subgroup analysis demonstrated that performance of the 1 
GALAD was independent of cirrhosis. The lack of BCLC classification and absence of 2 
histological NASH confirmation in the NAFLD surveillance cohort are another 3 
limitation.  4 
In conclusion, our data confirm that the GALAD score is superior to individual serum 5 
markers for detection of HCC in NASH, independent of tumor stage or cirrhosis.  6 
The findings suggest, that GALAD should be investigated as potential tool for 7 
screening of NASH individuals to detect HCC at a resectable stage in a sufficiently 8 
large prospective study to identify a cut-off. 9 
 10 
 11 
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FIGURE LEGENDS:  1 
Figure 1: Performance of the GALAD model for detection of HCC in NASH. (A) 2 
GALAD achieved significantly higher area under the curve (AUC) than the individual 3 
biomarkers AFP, AFP-L3, and DCP in the overall cohort (n=; P<0.0005) and in the 4 
subgroup of early stage HCC (BCLC A; n=28) (B), except DCP. (C) GALAD could 5 
also separate NASH-HCC within Milan criteria (n=25) from NASH controls with good 6 
performance. 7 
 8 
Figure 2: Cirrhosis does not influence performance of GALAD for detection of 9 
HCC or early HCC. To assess if cirrhosis or absence thereof has an impact on 10 
GALAD, analysis were divided into NASH-HCC with cirrhosis (A; n=93) vs. NASH 11 
cirrhosis (n=47) and NASH-HCC without cirrhosis (B; n=30) vs. NASH without 12 
cirrhosis (n=182). GALAD achieved good performance in the cirrhotic subpopulation 13 
and excellent performance in non-cirrhotic patients. Within the subgroup of early 14 
HCC (BCLC A) with cirrhosis (C; n=22) acceptable performance was reached. 15 
Separation of early HCC without cirrhosis (D; n=7) from non-cirrhotic controls was 16 
possible with good performance. 17 
Figure 3: Rise of GALAD in NAFLD patients under surveillance occurs prior 18 
HCC diagnosis. In a surveillance cohort of NAFLD patients (n=389) GALAD was 19 
significantly higher in patients developing HCC. Rise of the GALAD score 20 
represented by (A) LOWESS plot and (B) linear regression based aggregate curves 21 
occurs months or even years before HCC development (n=17). (C) All available 22 
GALAD values of NAFLD patients developing HCC under surveillance (n=26) plotted 23 
against time prior HCC diagnosis resulted in a significant (p<0.0001) correlation. A 24 
non-linear (three parameter) fitting model through all datapoints resulted in an 25 
estimate curve (D), suggesting that the cut-offs -0.63 and -1.27 would have been 26 
surpassed 200 or even 500 days, respectively, prior HCC diagnosis. Timepoint "0" in 27 







Abbreviations:  AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI body mass index;  DCP, Des-gamma carboxyprothrombin; HCC, 1 
hepatocellular carcinoma; NASH, nonalcoholic steatohepatitis;  *P <=  .05; **P <= .01; ***P <= .001. 2 
All continuous variables are presented as median (with interquartile range). Values are expressed as medians and range, i.e., first and third quantiles. 3 
Significance is based  on either Wilcoxon signed rank tests or -tests, depending on variable type.  4 
Table 1: Patient characteristics 
 
All German centers Ogaki, Japan 
Variable NASH-Non HCC (n=231) NASH-HCC (n=126) NASH-Non HCC (n=363) NASH-HCC (n=26) 
Age (years) 52 (44, 58.5) 70.5 (64, 75) *** 68 (59, 74) 62 (45, 75) 
Sex male, n(%) 120 (51.9) 84 (67.2), n=125 ***  180 (49.6) 21 (80.8) 
GALAD -3.96 (-5.22, -2.6) 2.93 (0.77, 7.62), n=125 *** -3.24 (-4.21, -2.20) -0.30 (-3.29, 13.32) 
AFP (ng/ml) 2.5 (1.8, 4.3) 16.1 (5.7, 497.7) *** 2.4 (1.7, 3.5) 5.9 (2.2, 35968) 
AFP-L3 (%) 0.1 (0.1, 4.2) 13.2 (6.65, 46.6) *** 0.5 (0.5, 0.5) 0.85 (0, 33.5) 
DCP (ng/ml) 0.37 (0.28, 0.5) 14.73 (1.14, 149.56) *** 0.20 (0.17, 0.25) 0.28 (0.13, 602.4) 
Cirrhosis, n(%) 48 (20.9), n=230 96 (76.2) *** 71 (19.6), n=362 (FIB4≥3.25) 13 (81.3), n=16 (FIB4≥3.25) 
Child-Pugh grade,  
n(%) 
No cirrhosis 146 (76.4), n=191 28 (23.1), n=121 *** Not available Not available 
A 34 (18.3), n=191 69 (57.0), n=121 *** Not available Not available 
B 10 (5.2), n=191 20 (16.5), n=121 *** Not available Not available 
C 1 (0.5), n=191 4 (3.3), n=121 *** Not available Not available 
BCLC stage,  
n(%) 
A Not applicable 29 (23.2), n=125 Not applicable Not available 
B Not applicable 61 (48.8), n=125 Not applicable Not available 
C Not applicable 30 (24.0), n=125 Not applicable Not available 
D Not applicable 5 (4.0), n=125 Not applicable Not available 
Albumin (g/l) 44 (40, 46.45), n=223 39 (33, 43), n=119 *** 44 (42, 46) 40.5 (29, 48) 
Bilirubin (µmol/l) 8.6 (5.1, 13.2), n=225 12.1 (8.6, 20.5), n=125 *** 11.97 (8.55, 17.1), n=361 11.12 (5.13, 25.65) 
BMI (kg/m2) 29 (26.5, 33), n=219 29 (26, 33), n=119 25 (23.1, 27.1), n=237 27 (18.7, 34.7) 
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Supplementary Figure 1: Patient selection and structure of presented cohorts. A Algorithm of patient selection for enrollment in the 
German retrospective cohort. B Japanese prospective surveillance program: Among 389 patients with NAFLD in a rigorous, prospective, surveillance 
program at the Ogaki Municipal Hospital, Japan, 29 developed HCC. Of these patients with HCC development during surveillance, 26 had GALAD 
values available prior HCC diagnosis, including 17 patients, who had more than one set of biomarkers recorded before HCC was diagnosed. 
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Supplementary Figure 3: Performance of GALAD and FIB-4 index for separation 
of NASH HCC from NASH controls. As cirrhosis could be a confounding factor for 
the predictive value of GALAD, performance of FIB-4 index was compared to GALAD 
(AUC: 0.96), reaching significantly lower AUC (0.81). Overall performance measured 
by AUC was lower for FIB-4 than for individual serum markers of the GALAD score. 
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Supplementary Table 1: Performance of GALAD at the cut-offs -0.63 and -1.334 






PPV1 NPV2 Correctly 
identified 
[%] 
Cut-off -0.63 (previously established) 
All HCC 
(n = 125) 




68 95.24 0.61 0.96 92.6 
BCLC A 
(n = 29) 




(n = 7) 
85.71 96.15 0.46 0.99 95.8 
Cut-off -1.334 (identified in this study) 
All HCC 
(n = 125) 




84 90.91 0.50 0.98 90.2 
BCLC A 
(n = 29) 




(n = 7) 
85.71 93.41 0.33 0.99 93.1 
1: positive predictive value; 2: negative predictive value; *: vs. non-cirrhotic NASH 
controls n = 182. 
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Supplementary Table 2: Patient data of Japanese Sub-group with more than 1 
GALAD value available prior HCC diagnosis (n =17) 
 
Ogaki, Japan 
Variable NASH-Non HCC (n=363) NASH-HCC (n=17) 
Age (years) 68 (59, 74) 69 (66, 77) 
Sex male, n(%) 180 (49.6) 12 (70.6) 
GALAD -3.24 (-4.21, -2.20) -0.60 (-1.49, 0.72) 
AFP (ng/ml) 2.4 (1.7, 3.5) 8.2 (4.4, 13.6) 
AFP-L3 (%) 0.5 (0.5, 0.5) 5.2 (0.5, 8.7) 
DCP (ng/ml) 0.20 (0.17, 0.25) 0.40 (0.22, 1.03) 
Cirrhosis, n(%) 71 (19.6), n=362 (FIB4≥3.25) 13 (81.3), n=16 (FIB4≥3.25) 
Child-Pugh grade,  
n(%) 
No cirrhosis Not available Not available 
A Not available Not available 
B Not available Not available 
C Not available Not available 
BCLC stage,  
n(%) 
A Not applicable Not available 
B Not applicable Not available 
C Not applicable Not available 
D Not applicable Not available 
Albumin (g/l) 44 (42, 46) 38.5 (34.5, 43.5), n=16 
Bilirubin (µmol/l) 11.97 (8.55, 17.1), n=361 23.09 (11.97, 25.65), n=16 
BMI (kg/m2) 25 (23.1, 27.1), n=237 24.1 (21.6, 27.3), n=7 
Diabetes, n(%) 140 (38.6) 15 (88.2) 
  
Abbreviations:  AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI body mass 
index;  DCP, Des-gamma carboxyprothrombin; HCC, hepatocellular carcinoma; NASH, 
nonalcoholic steatohepatitis; 
*P <=  .05; **P <= .01; ***P <= .001. 
All continuous variables are presented as median (with interquartile range). Values are 
expressed as medians and range, i.e., first and third quantiles. Significance is based  on either 
Wilcoxon signed rank tests or -tests, depending on variable type.  
 
 
The GALAD score as potential screening test for hepatocellular carcinoma in 






Patients in the German Multicenter cohort 
Patients of the retrospective German multicenter cohort were recruited from 
University Hospital (UH) Essen (collected between 2005 and 2016), UH Hannover 
(collected between 2008 and 2013), UH Leipzig (collected between 2010 and 2015), 
UH Mainz (collected between 2001 and 2013), UH Hamburg (collected between 2011 
and 2015), UH Heidelberg (collected between 2012 and 2014), UH Magdeburg 
(collected between 2011 and 2013) and UH Freiburg (collected between 2010 and 
2011). Cohort stratification is described in detail in Supplementary Figure 1. For 
HCC patients the biomarker measurement (AFP, AFP-L3, DCP) had to be performed 
within 3 months of HCC diagnosis and prior any treatment administration to be 
eligible for analysis. 
Patients in the NASH-control group were recruited retrospectively, when all of the 
following three criteria were fulfilled: 1. Absence of any clinical evidence of HCC at 
the time the serum samples were taken. 2. Clinical presentation typical for those 
individuals that would be included in a screening program. 3. At least 6 months of 
follow up after GALAD score assessment to confirm the absence of HCC. 
Patients with two or more diseases, which would predispose for cirrhosis and/or 




Measurements of serological biomarkers 
AFP, AFP-L3 and DCP were measured in the same serum sample (stored at -20°C) 
using the µTASWakoTM i30 fully automated immunoanalyzer (FUJIFILM Wako 
Chemicals Europe GmbH, Neuss, Germany). Liquid-phase binding assays followed 
by capillary electrophoresis and fluorescence detection in microchips were used for 
analysis18. Assay sensitivities were 0.3 ng/mL for AFP and 0.1 ng/mL for DCP. The 
percentage of AFP-L3 was determined in samples where both subfractions (AFP-L1 
and AFP-L3) were >0.3 ng/mL. 
 
GALAD 
The GALAD model25 was calculated according to the equation: 
 = −10.08 + 0.09 ∗  + 1.67 ∗  + 2.34 ∗  + 0.04 ∗ _ 3
+ 1.33 ∗ !" 
with gender set as 1 for males and 0 for females. 
The linear predictor (Z) is used to estimate the probability of HCC in an individual 
patient (ranging from 0 to 1) using the following equation: #"" 	= 	%&/1 +
%&.  
GALAD Score Detects Early Hepatocellular Carcinoma in an International 1 
Cohort of Patients With Nonalcoholic Steatohepatitis 2 
Need to Know: 3 
BACKGROUND AND CONTEXT: The performance of ultrasound screening for 4 
hepatocellular carcinoma (HCC) is limited, especially in patients with nonalcoholic 5 
steatohepatitis (NASH).  6 
 7 
NEW FINDINGS: In a retrospective analysis of patients with NASH in Germany, the 8 
GALAD score (based on patient features and laboratory test results) detected HCC 9 
(even early-stage tumors) with greater than 90% sensitivity and specificity—higher 10 
values than for any biomarker alone. In a prospective study, the GALAD score 11 
identified patients who developed HCC as early as 1.5 y before their diagnosis.  12 
 13 
LIMITATIONS: The number of patients with early-stage HCCs was small and the 14 
frequency of liver cirrhosis in our HCC population might not be typical.  15 
 16 
IMPACT: The GALAD score might be used in surveillance for HCC in patients with 17 
NASH. 18 
 19 
Lay Summary: Analysis of several factors, including patient sex, age, and blood 20 
levels of several proteins, can identify patients with NASH who are at high risk for 21 
HCC. 22 
 23 
